As of January 1, 2020, the Centers for Medicare & Medicaid Services (CMS) will provide reimbursement for certain angioplasty and stenting procedures performed outside the hospital outpatient setting.
Percutaneous Coronary Intervention (PCI) is a non-surgical procedure that uses a catheter to place a stent in the heart to treat atherosclerosis.
Both the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions provided letters of support for the changes.
This is exciting news for medical device companies with coronary stenting products, paving the way for streamlined reimbursement in ambulatory surgery centers (ASC) and other outpatient facilities.
Proximo Medical recently announced a partnership with CeloNova Biosciences, Inc. and the COBRA PzF NCS, the world’s first and only non drug-eluting, nanocoated coronary stent.
“By streamlining the reimbursement process in ASC’s, our sales team can quickly put innovations into physicians hands, providing improved treatment options for patients,” states Brett Martin, CEO, Proximo Medical.
Proximo Medical is currently looking for experienced medical device sales professionals for our interventional cardiology team. Click HERE for more information.